Skip to content

Clinical Investigation of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)

Clinical Investigation of AcrySof® IQ ReSTOR® Multifocal Toric Intraocular Lens Models SND1T3/ SND1T4/ SND1T5/ SND1T6

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01424189
Enrollment
677
Registered
2011-08-26
Start date
2011-07-31
Completion date
2013-01-31
Last updated
2018-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataracts

Keywords

Cataract surgery, Intraocular lens

Brief summary

The purpose of this study is to evaluate the safety and effectiveness of an investigational multifocal toric intraocular lens (IOL) compared to an FDA-approved multifocal IOL.

Detailed description

Participants 21 years and older within the targeted astigmatism range and in need of cataract extraction in both eyes were consented and randomized in a 2:1 ratio at each investigative site to receive either the AcrySof® IQ ReSTOR® Multifocal Toric IOL or the control AcrySof® ReSTOR® Multifocal IOL in both eyes. Each participant completed a preoperative examination of both eyes, implantation of the IOL at the operative visit for each eye, and up to 8 postoperative visits, with monocular testing at Day 1-2, Day 7-14, and Day 30-60 and binocular testing at Day 120-180 and Day 340-420/Visit 5 following the second implantation. The eye with the greater amount of astigmatism was implanted first (first operative eye). The second eye implant was intended to occur within 30 days after the first eye implant but not prior to 7 days after the first eye implant. Both eyes needed to qualify under inclusion/exclusion criteria at the preoperative visit. If the first eye was excluded during surgery, the second eye was not eligible. If the second eye was excluded during surgery, only the first eye was followed.

Interventions

Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient

DEVICEAcrySof® ReSTOR® Multifocal IOL Model SA60D3

Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with bilateral cataracts; * Able to comprehend and sign a statement of informed consent; * Calculated lens power and astigmatism within the available range; * Willing and able to complete all required postoperative visits; * Planned cataract removal by phacoemulsification; * Potential postoperative visual acuity of 0.2 logMAR or better in both eyes; * Preoperative astigmatism in both operative eyes as described in the clinical protocol; Note: Corneal incisions made to reduce astigmatism will not be allowed during the course of the study. * Clear intraocular media other than cataract in study eyes; * Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR in each eye; * Pupil size greater than or equal to 6 mm after dilation; * Able to undergo second eye surgery within 30 days of the first eye surgery; * Other protocol-specified inclusion criteria may apply.

Exclusion criteria

* Significant irregular corneal aberration as demonstrated by corneal topography; * Keratopathy/Kerectasia - any corneal abnormality, other than regular corneal astigmatism; * Any inflammation or edema (swelling) of the cornea; * Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted (by subjective assessment of the retina) to cause future acuity losses to a level worse than 0.2 logMAR; * Reasonably expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy); * Previous corneal refractive surgery; * Amblyopia; * Clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy); * Diabetic retinopathy; * Extremely shallow anterior chamber, not due to swollen cataract; * Microphthalmos; * Previous retinal detachment; * Previous corneal transplant; * Recurrent severe anterior or posterior segment inflammation of unknown etiology; * Rubella or traumatic cataract; * Iris neovascularization; * Glaucoma (uncontrolled or controlled with medication); * Aniridia; * Optic nerve atrophy; * Pregnancy; * Current participation in another investigational drug or device study that may confound the results of this investigation; * Other planned ocular surgery procedures, including, but not limited to LASIK, astigmatic keratotomy and limbal relaxing incisions, for the duration of the study; * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Mean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 5Month 12 from second eye implantationVisual acuity (VA) was measured monocularly (each eye separately) without visual correction using a 100% contrast ETDRS (Early Treatment of Diabetic Retinopathy Study) chart positioned 4 meters (m) from the participant under well-lit conditions. +0.25 diopter (D) spherical power was applied to correct for optical infinity. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.
Mean Monocular Uncorrected Near Visual Acuity (UCNVA) at Fixed Distance at Visit 5Month 12 from second eye implantationVA was measured monocularly without visual correction using a hand-held ETDRS chart at a fixed distance that differed by lens model implanted. The logMAR ETDRS near visual acuity chart was designed for use at 40 cm; results obtained at other distances were converted to reflect the change in apparent letter size that results from the change in distance. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.
Rate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5Month 12 from second eye implantationThe rate of actual and potential secondary surgical interventions (SSIs) related to the optical properties of the IOL was estimated. If an ocular surgical intervention was performed, it qualified as an actual SSI; however; if the participant met the protocol-specified criteria that would warrant an SSI, but didn't actually undergo the SSI, it qualified as a potential SSI. Rate is presented as percentage of participants.

Secondary

MeasureTime frameDescription
Rate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Month 12 from second eye implantationVisual disturbances/distortions were reported by the participant on the Assessment of Photic Phenomena and Lens EffectS (APPLES) questionnaire, a Patient Reported Outcome (PRO) questionnaire intended to evaluate 10 distinct visual phenomena associated with cataract extraction and IOL implantation. The first 20 questions addressed both the frequency and severity of the phenomena using a 4-point categorical scale ranging from never to always (frequency) or none to severe (severity). The final (21st) question indicated whether the participant answered the questions based on experiences with or without glasses. The participant completed the assessment as a retrospective analysis of the previous week. Rate is presented as the percentage of participants with severity score severe for the visual phenomenon.

Participant flow

Recruitment details

Participants were recruited from 21 investigative sites located in the United States.

Pre-assignment details

Of the 677 participants enrolled, 103 were exited prior to randomization as screen failures. This reporting population includes all participants with successful IOL implantation in at least 1 eye (574).

Participants by arm

ArmCount
ReSTOR Toric IOL
AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
386
ReSTOR IOL
AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
188
Total574

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event10
Overall StudyDeath31
Overall StudyLost to Follow-up41
Overall StudySubject moved10
Overall StudyWithdrawal by Subject44

Baseline characteristics

CharacteristicReSTOR Toric IOLTotalReSTOR IOL
Age, Continuous66.91 years
STANDARD_DEVIATION 9.2
67.38 years
STANDARD_DEVIATION 8.88
68.36 years
STANDARD_DEVIATION 8.13
Sex: Female, Male
Female
240 Participants376 Participants136 Participants
Sex: Female, Male
Male
146 Participants198 Participants52 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
48 / 38628 / 188
serious
Total, serious adverse events
45 / 38621 / 188

Outcome results

Primary

Mean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 5

Visual acuity (VA) was measured monocularly (each eye separately) without visual correction using a 100% contrast ETDRS (Early Treatment of Diabetic Retinopathy Study) chart positioned 4 meters (m) from the participant under well-lit conditions. +0.25 diopter (D) spherical power was applied to correct for optical infinity. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.

Time frame: Month 12 from second eye implantation

Population: This analysis population includes all participants with successful IOL implantation in the first implanted eye with data at visit.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
ReSTOR Toric IOLMean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 50.126 logMARStandard Error 0.013
ReSTOR IOLMean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 50.125 logMARStandard Error 0.015
Primary

Mean Monocular Uncorrected Near Visual Acuity (UCNVA) at Fixed Distance at Visit 5

VA was measured monocularly without visual correction using a hand-held ETDRS chart at a fixed distance that differed by lens model implanted. The logMAR ETDRS near visual acuity chart was designed for use at 40 cm; results obtained at other distances were converted to reflect the change in apparent letter size that results from the change in distance. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the first operative eye.

Time frame: Month 12 from second eye implantation

Population: This analysis population includes all participants with successful IOL implantation in the first implanted eye with data at visit.

ArmMeasureValue (MEAN)Dispersion
ReSTOR Toric IOLMean Monocular Uncorrected Near Visual Acuity (UCNVA) at Fixed Distance at Visit 50.19 logMARStandard Deviation 0.015
ReSTOR IOLMean Monocular Uncorrected Near Visual Acuity (UCNVA) at Fixed Distance at Visit 50.24 logMARStandard Deviation 0.017
Primary

Rate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5

The rate of actual and potential secondary surgical interventions (SSIs) related to the optical properties of the IOL was estimated. If an ocular surgical intervention was performed, it qualified as an actual SSI; however; if the participant met the protocol-specified criteria that would warrant an SSI, but didn't actually undergo the SSI, it qualified as a potential SSI. Rate is presented as percentage of participants.

Time frame: Month 12 from second eye implantation

Population: This analysis population includes all participants with attempted IOL implantation (successful or aborted after contact with the eye). For participants with actual SSIs, performance testing outcomes conducted prior to the secondary intervention were carried forward to the final analysis.

ArmMeasureGroupValue (NUMBER)
ReSTOR Toric IOLRate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5First Implanted Eye1.04 percentage of participants
ReSTOR Toric IOLRate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5Second Implanted Eye0.52 percentage of participants
ReSTOR IOLRate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5Second Implanted Eye2.13 percentage of participants
ReSTOR IOLRate of Actual and Potential Secondary Surgical Interventions (SSIs) Related to the Optical Properties of the IOL for First and Second Operative Eyes Separately at Visit 5First Implanted Eye2.13 percentage of participants
Secondary

Rate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5

Visual disturbances/distortions were reported by the participant on the Assessment of Photic Phenomena and Lens EffectS (APPLES) questionnaire, a Patient Reported Outcome (PRO) questionnaire intended to evaluate 10 distinct visual phenomena associated with cataract extraction and IOL implantation. The first 20 questions addressed both the frequency and severity of the phenomena using a 4-point categorical scale ranging from never to always (frequency) or none to severe (severity). The final (21st) question indicated whether the participant answered the questions based on experiences with or without glasses. The participant completed the assessment as a retrospective analysis of the previous week. Rate is presented as the percentage of participants with severity score severe for the visual phenomenon.

Time frame: Month 12 from second eye implantation

Population: This analysis population includes all participants with attempted IOL implantation (successful or aborted after contact with the eye).

ArmMeasureGroupValue (NUMBER)
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Blurred vision0.8 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Color distortion0.0 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Flat lines look curved0.0 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Straight lines look tilted0.0 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Double vision0.8 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Feeling sick due to visual distortion0.0 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Glare3.5 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Halos7.5 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Hazy vision1.3 percentage of participants
ReSTOR Toric IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Starbursts4.3 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Halos11.0 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Blurred vision0.0 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Feeling sick due to visual distortion0.5 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Color distortion0.0 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Starbursts8.8 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Flat lines look curved0.0 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Glare2.7 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Straight lines look tilted0.0 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Hazy vision0.5 percentage of participants
ReSTOR IOLRate of Severe Visual Disturbances/Distortions Reported on the Assessment of Photic Phenomena & Lens EffectS (APPLES) Questionnaire at Visit 5Double vision0.0 percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026